Atopic dermatitis care is evolving with flexible biologic dosing, expanded pediatric options, and novel oral, topical, and systemic therapies.
|Slideshows|September 14, 2018
Must read studies on atopic dermatitis
Author(s)Dermatology Times Staff
Listen
0:00 / 0:00
In this slideshow, we highlight some of the most innovative and important clinical advances in the treatment of atopic dermatitis.
Advertisement
In this slideshow, we highlight some of the most innovative and important clinical advances in the treatment of atopic dermatitis.
Advertisement
Related to this article
ATI-052 improved disease severity and itch in a phase 1b trial of patients with severe atopic dermatitis, with no grade 3 or 4 adverse events.
The September issue highlights advances in alopecia areata, cosmetic SPF, psoriasis treatment, teledermatology, and atopic dermatitis.
Two-year oral IL-23 data, GLP-1 biomarker findings, and a nonsurgical option for superficial basal cell carcinoma headline the sessions covered in Las Vegas.
A retrospective claims analysis of 2897 matched pairs found hazard ratios of 0.48 to 0.67 for new atopic disease with dupilumab vs systemic corticosteroids in children.
Advertisement
Advertisement